

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
COLLIS et al.Examiner: Morris, Patricia **RECEIVED
CENTRAL FAX CENTER**Application No.: **09/871,564**

Art Unit: 1625


DEC 01 2005Filed: **05/31/2001**Title: **Heteroaryl-Cyclic Acetals****TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, at 571-273-8300 on

August 26, 2005

Date of Transmission

Signature

**RESPONSE TO RESTRICTION/ELECTION REQUIREMENT**Mail Stop TC1600
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

In response to the Restriction/Election requirement imposed by the Examiner in the above-referenced application (Office Communication mailed April 28, 2005), Applicants hereby elect Group I for further prosecution.

Group I includes, as determined by the Examiner, the subject matter of claims 1-15, drawn to compounds, classified in classes 540, 544, 546, 548 and 549, in various subclasses. Furthermore, Applicants elect for examination purposes the specie of Example 1 as requested by the Examiner. This compound is 4-[5-(5,5-dimethyl-[1,3]dioxan-2-yl)-2-(4-fluoro-phenyl)-2H-pyrazol-3-yl]-pyridine.

Upon allowance of the above-elected subject matter, the claims will be amended to reflect such election. Applicants reserve the right to pursue the remaining non-elected subject matter in one or more timely filed divisional applications.

Respectfully submitted,


James W. Bolcsak, Reg. No.: 39,912
Attorney/Agent for ApplicantAventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-5922
Telefax (908) 231-2626

Aventis Docket No. CA2295 USCNT